Summary
This filing is an amendment to a previous 8-K, clarifying and expanding upon compensation arrangements for Gilead Sciences, Inc.'s named executive officers. The primary focus is on stock option and performance share awards granted on January 22, 2007, under the company's 2004 Equity Incentive Plan. These awards are designed to incentivize executive performance and align their interests with shareholders by tying compensation to the company's stock performance and revenue growth relative to the AMEX Biotech-Pharmaceutical Index (BPI Index). Investors should note that the performance shares have a complex structure, with vesting contingent upon achieving specific Total Stockholder Return (TSR) and revenue growth targets compared to the BPI Index over several tranches, spanning up to March 2010. The potential payout for performance shares can range from 0% to 200% of the allotted amount, depending on performance. The filing also outlines provisions for accelerated vesting in the event of a change in control and specifies forfeiture conditions upon termination of employment, with exceptions for death or disability.
Key Highlights
- 1Gilead Sciences granted stock options and performance shares to its named executive officers on January 22, 2007.
- 2The stock options were granted with an exercise price of $65.58, reflecting the closing price on January 19, 2007.
- 3Options vest over five years, with 20% vesting after the first year and the remainder vesting quarterly thereafter.
- 4Performance shares are tied to the company's Total Stockholder Return (TSR) and revenue growth relative to the AMEX Biotech-Pharmaceutical Index (BPI Index).
- 5The performance share payout can range from 0% to 200% of allotted shares based on achieved performance metrics.
- 6Vesting of performance shares is structured in three tranches with performance measurement periods extending up to March 2010.
- 7Change in control provisions allow for accelerated vesting of performance shares under certain conditions.